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ABSTRACT 
 
           The use of opioid medications is a rapidly growing problem in the United States. 
Although these medications are effective for short term pain relief, their long-term implications 
on the brain and interactions with other substances are still unknown. Despite the gaps in 
knowledge of the long-term implications or efficacy of opioids, there are still more than 200 
million prescriptions written annually for opioid analgesics (Semenkovich et al., 2014). In 
addition to the overuse of these medications, they can cause interactions with other substances, 
some of which can cause severe cases of poly-intoxication. As the use of these medications 
continues to increase, so does the number of deaths that result from the misuse of these 
medications. According to the American Medical Association, "after alcohol intoxication, 
opioids are the most common cause of poisoning in presenting to North American emergency 
departments" (Lewis et al., 2015). This increase in emergency department usage as a result of 
opioid-related cases leads to an overall increase in healthcare costs. While researching the long-
term effects of opioids on the brain, their interactions with other substances, and potential side 
effects that can arise from prolonged opioid usage, more concrete options must be considered. 
Finding effective ways to treat these patients and using alternative methods for pain relief can 
not only help people in need of pain relief but also our healthcare system as a whole. 
                               
INTRODUCTION 
 The use of opioid analgesics is a rapidly growing problem in the United States. Although 
these medications are effective for short term pain relief, their long-term implications on the 
brain and interactions with other substances are still unknown. While it is understandable that 
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pain relief is an essential part of healthcare, it can also be a complicated topic to address due to 
its subjectivity. As the amount of analgesics available to the population continues to grow, so do 
the number of options available for pain relief. Although we know a substantial amount of 
information about how these medications work, we can never completely understand how an 
individual will react to pain medications, especially when it comes to opioid analgesics due to 
the differences in each person's brain chemistry. With the growing use of prescription opioid 
medications, the potential for abuse also increases. While there is little information on the cost of 
nonmedical use of prescription opioids, the few studies that have been done on this subject have 
shown extremely high costs associated with this. Research shows that the economic cost of the 
nonmedical use of prescription opioids in the United States alone is more than $50 billion 
annually (Hansen et al., 2011).   
     To understand the opioid epidemic, we must first understand how opioid mediations 
impact the brain. While every patient will respond to an opiate differently, a basic understanding 
of the neurological implications of opioid usage is crucial in deciphering how these medications 
work. When opiates of any kind are used, they are broken down into chemicals that travel 
through the bloodstream to the brain, where they attach to opioid receptors. The mu-opioid 
receptor is the main target for morphine, heroin, and most other opioid analgesics. While all 
individuals have these receptors in their brains, differences in genetic makeup can cause 
variations in the mu-receptor. This binding of the chemicals with the target receptors triggers the 
mesolimbic reward system, the biochemical pathway associated with reward and pleasure. Once 
activated, this pathway generates signals in the ventral tegmental area (VTA), which results in 
the release of the neurotransmitter dopamine from the nucleus accumbens; this release of 
dopamine is what generates feelings of pleasure in our brain. In addition to dopamine causing 
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feelings of pleasure, other areas of the brain associate these feelings with the opiate used, which 
gets created into lasting memories. These memories can lead to future cravings, potentially 
causing an individual to use the medication more than the prescribed dose (Kosten et al., 2002). 
             
                           NEUROLOGICAL IMPLICATIONS OF OPIOID USE 
      The amygdala is an essential brain structure that regulates emotional responses. The central 
nucleus of the amygdala is crucial in the control of the emotional aspects in chronic pain and the 
learning process of associating a particular stimulus, in this case, the opiate, with reward 
association. "[T]he central nucleus of the amygdala is the part of the brain that focalizes 
emotional stimuli associated with chronic pain and addictive opioids," which provides an 
appropriate neural pathway to draw connections between opioids medications and their 
continued usage. (Zhang et al., 2014). Additionally, in a study done by Dr. Zhi Zhang and 
colleagues, it was shown that the use of opioids over time could cause changes in the synaptic 
plasticity of neurons, which can remain in the brain regardless of opioids being present or not. As 
an individual ingests opioid medications over a period of time, different areas of the brain are 
affected in various ways. In a recent study conducted by Dr. Jaymin Upadhyay and colleagues, it 
was shown that prescription opioid-dependent patients showed evidence of a specific structural 
abnormality in the neural reward-processing network present in the brain. (Younger et al.,2011). 
When compared to ten age-matched controls, the researchers found decreased gray matter 
volume in the bilateral amygdala.  
 The amygdala is crucial in reward processing, and an essential structure is known to 
underlie opioid-related addiction, dependence, and tolerance. The results of this study concluded 
that opioid exposure has an extensive range of effects on the amygdala, some of which include a 
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decrease in sensitivity of the mu-opioid receptor, modified GABAA receptor functioning, and 
altered glutamate receptor targeting (Younger et al.,2011). While mu-opioid receptor sensitivity 
is a topic that has previously been discussed, the GABAA and glutamate receptors are also a 
critical part of understanding the opioid epidemic as a whole. GABA is the major inhibitory 
neurotransmitter in the brain, and glutamate is the major excitatory neurotransmitter in the brain. 
While there are many ways opioids interact with the body, "data suggests opioids exert their 
excitatory action in the brain indirectly by inhibiting the release of GABA" (Kalyuzhny et al., 
2000). By indirectly targeting these receptors, opioid medications can cause irreversible damage 
to the brain. Results of the study done by Dr. Upadhyay and colleagues showed that in the 
patient group, there was a significant reduction in the functionality of the anterior insula, nucleus 
accumbens, and amygdala. Once the results of the study were analyzed, there was a strong 
correlation with a longer duration of opioid usage and more significant changes in functional 
connectivity in the afferent and efferent pathways of the amygdala.  
 In addition to functionality changes in different areas of the brain, recent studies have 
shown prolonged or repeated exposure to a drug of abuse, such as an opioid, causes structural 
changes in specific neuronal cells that can remain even after the drug is discontinued. In the case 
of opiates, repeated exposure can decrease the size of dendrites and soma of neurons in the VTA. 
The consequences of these neuronal changes are mostly unknown, but these changes could result 
in a down-regulation of dopamine activity, which can potentially contribute to the anxiety and 
restlessness associated with opiate withdrawal. Furthermore, chronic exposure to opioid 
medications can also reduce the regeneration of new neurons in the adult hippocampus, causing 
further complications (Nestler, 2001). The effects that this has on the functional significance of 
the hippocampus is still not completely understood, but due to the role the hippocampus plays in 
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learning and memory, long-term opioid usage could potentially cause changes in these cognitive 
processes. These findings suggest that the continued use of opioid medications is associated with 
structural and functional changes in the brain regions associated with impulse control, reward, 
and motivational functions.  
   
                        OPIOID DEPENDENCE VS. ADDICTION 
       While it is known that the prolonged usage of opiates results in tolerance to the 
medication, differences in the genetic makeup of individuals can play a role in how tolerance to 
the opioid will manifest. Tolerance can be defined as "the need to increase the dose to achieve 
the same effect," and can develop for both the euphoric effects that an opiate produces as well as 
the analgesic effects. (Ballantyne et al.,2012). Numerous studies have shown that tolerance to 
different opiates will manifest at different rates, a phenomenon that is now called selective 
tolerance. For example, "tolerance to nausea, vomiting, sedation, euphoria, and respiratory 
depression occurs rapidly, but there is minimal development of tolerance to constipation and 
miosis." These findings suggest receptor-related differences in the development of tolerance. 
Additionally, it has been shown that the administration of benzodiazepines, in conjunction with 
an opiate, speeds up the development of tolerance. (Freye & Latasch, 2003). This change is 
likely due to the significant reduction in the secretion of GABA, a neurotransmitter that reduces 
the overall inhibitory effects of the nervous system, increasing analgesic effects of the drug.  
       Furthermore, it has been suggested that when using higher potency opiates, which 
produce more significant effects when bound to receptors, fewer receptors are needed to produce 
sufficient analgesic effects. Receptor downregulation and desensitization have been observed in 
individuals who use opioids for prolonged periods and have shown to play a critical role in the 
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development of tolerance and dependence (Harrison et al., 1998). Due to the decrease in 
receptors needed for higher potency opiates, tolerance is less likely to manifest. Once tolerance 
to an opiate has developed, an increase in the dose of the medication may be necessary to 
produce similar analgesic effects.  
       While most individuals do not take an opiate for the first time thinking they will develop 
an addiction, addiction can occur over time. There is no concrete definition as to why this 
happens, but it can be concluded that the chemical makeup of the opiate and the effect it has on 
the different pathways of the brain play a large part in it. Addiction and dependence are not 
synonymous terms, but they both stem from the same fundamental principles. From a biological 
perspective, opioid addiction can be explained by neurological variations that arise when 
exogenous opioids are used. Dependence can be defined as the physiological response an 
increase in tolerance or to the withdrawal of a drug (Ballantyne et al., 2012). Dependence can 
manifest as withdrawal symptoms, such as anxiety, chills, and insomnia, which can occur after 
the sudden tapering down of opioid usage or complete termination of the opioid. When 
understanding how addiction and dependence differ, it needs to be understood that addiction is 
defined as persistent, atypical "opioid-seeking behaviors" that result in irreversible changes in 
brain structure and function (Ballantyne et al., 2012). There are different theories of addiction, 
but the Goldstein hypothesis presents the most recognizable link between the mu-receptor 
variations and opioid addiction. This hypothesis states that in addicts, the amount of endogenous 
opioid present may be too low, causing the addict to attempt to restore this deficiency by 
increasing the use of external opioids. This leads us to believe that an inadequate surface 
expression or inadequate activity of the mu-opioid receptor may predispose an individual to 
(opiate) addiction (Goldstein, 1994). 
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       Additionally, numerous genetic variations can cause polymorphisms in the coding region 
of the mu-opioid receptor. These polymorphisms can lead to the upregulation or downregulation 
of the gene encoding for the receptor. Furthermore, according to the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5), tolerance and withdrawal (physical dependence) that is 
developed during medical drug treatment are excluded from diagnostic criteria for substance use 
disorder. Therefore, any tolerance or withdrawal symptoms that manifest during treatment are 
not taken into consideration, and the diagnosis is solely based on aberrant or drug-seeking 
behaviors (Ballantyne et al., 2012). For individuals who are treated with opioid medications long 
term, addictive behaviors may surface when the opioid is suddenly stopped, or the dosage is 
reduced due to the alterations in brain structure that arise from the long-term usage of opioid 
medications. While there is a substantial amount of literature on the effects of long-term opioid 
exposure on the brain, the effects of their short-term usage are still mostly unknown.   
 
                         INTERACTIONS WITH OTHER SUBSTANCES 
     With the increasing rate of opioid medications being prescribed, there has also been an 
increase in the amount of new synthetic opioid analogs being created. While these new 
medications are very potent in their analgesic effects, they can cause fatal side effects when 
combined with other substances. In fact, "[f]entanyl analogs are more potent than fentanyl, 
which is 50 times more potent than morphine" (Perez-Mana et al.,2018). Additionally, some 
fentanyl analogs have a much longer duration of action, which can cause more severe 
interactions with other substances. When understanding how opiates interact with other 
substances, it is crucial to understand how these medications are metabolized in the human body 
and how external substances, such as opioids, effect this metabolism. When an opiate is 
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administered, it is metabolized into active and non-active components. Taking a second 
substance can inhibit or accelerate the metabolism, resulting in an increase or decrease in the 
plasma concentration of the opiate. The increase in plasma concentration of a substance can lead 
to an increase in the therapeutic effects of the drug causing toxic effects. These drug-drug 
interactions will manifest differently in every individual, but they are divided into two main 
groups: pharmacodynamic and pharmacokinetic. Pharmacodynamic interactions refer to drug 
interactions that influence each other's effects directly. These interactions are usually synergistic, 
meaning "the effect of the two drugs taken together is greater than the sum of their separate 
effect at the same doses." When considering pharmacodynamic interactions, opioid medications 
and their analogs interact with other central nervous system depressant drugs such as 
antihistamines, benzodiazepines, and barbiturates, causing an increase in their therapeutic 
effects. Pharmacokinetic interactions occur when a second drug "interferes with the absorption, 
distribution, metabolism, or excretion" of the first opioid taken (Perez-Mana et al.,2018). 
Pharmacokinetic interactions can be seen with opioids and the administration of naloxone, a non-
selective opioid antagonist. Administration of an opioid antagonist such as naloxone can help 
reverse the effects of an opioid by acting as a competitive inhibitor of the mu-opioid receptor, 
binding to the receptor with a higher affinity than the opioid.  
       Due to the differences in the chemical diversity of these products, their exponential 
increase can complicate the proper absorption of these substances. While opioid analogs like 
fentanyl are excellent sources of pain relief, their potency and prolonged duration of action can 
increase the risk of severe interactions and potential toxicity. With the growing use of potent 
opioid analogs such as fentanyl, there has also been an increase in the amount of illicitly 
manufactured fentanyl, causing a spike in overdose deaths. (Prekupec et al., 2017). Substances 
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most commonly involved in these cases of "poly-intoxication are antidepressants, antihistamines, 
antipsychotics, benzodiazepines, analgesics, anesthetics, psychostimulants, other opioids, 
alcohol, and illegal drugs of abuse" (Perez-Mana et al.,2018). 
       Serotonin reuptake inhibitors, a class of antidepressant medication, can interact with 
opioid medications causing a significant increase in the plasma concentrations of the opiate. This 
increase is due to the effects of serotonin reuptake inhibitors and on Cytochrome P450 (CYP 
450), an enzyme system that aids in the metabolism of opioids. It has been shown that both 
fluoxetine and fluvoxamine have been considered for potential drug interactions with other 
opioids such as methadone and buprenorphine. (McCance-Katz et al.,2010). These 
antidepressants were shown to inhibit CYP450, resulting in decreased metabolism of methadone 
and buprenorphine. Fluoxetine was not associated with a clinically significant increase in 
methadone concentrations, but fluvoxamine has been reported to show marked increases in 
plasma methadone concentrations. Furthermore, when discontinued, fluvoxamine was correlated 
with the onset of opioid withdrawal. Subsequent opiate withdrawal is a risk associated with the 
administration of a medication that inhibits methadone metabolism, and discontinuation of the 
accompanying medication results in healthy methadone metabolism. Additional serotonin 
reuptake inhibitors that have shown to interact with methadone to some degree are sertraline, 
citalopram, duloxetine, and amitriptyline.  
  Anxiolytic medications such as benzodiazepines and sedative-hypnotics share some 
pharmacological properties such as sedation and altered cognition with methadone and 
buprenorphine. (McCance-Katz et al.,2010). When taken in conjunction with opioids, 
benzodiazepines act synergistically with opioids by facilitating inhibition at the GABA receptor 
and decreasing the effects of glutamate at its target receptor, leading to an increased risk of fatal 
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respiratory depression through agonist actions at the mu-opioid receptors in the medullary 
respiratory center. Diazepam and alprazolam, two commonly used anxiolytic medications, were 
also shown to cause fatal interactions with opiates such as methadone and buprenorphine; the 
ingestion of these two medications together resulted in fatalities in the most severe cases. 
(McCance-Katz et al.,2010). Reported fatalities due to the co-ingestion of alprazolam and 
methadone were due to pharmacodynamic interactions between the two, which was shown to 
increase the toxicity of the substances, suggesting exercising caution when prescribing the two 
simultaneously. Similar interactions occur between alcohol and opioid medications as those 
between anxiolytic medications and opioids.  
       Antihistamine medications, which are commonly prescribed for allergies, have also been 
shown to interact with certain opioid medications due to their effects on the CYP450 enzyme 
system. This enzyme system contributes to the metabolism of some antihistamine medications 
such as promethazine, diphenhydramine, and chlorpheniramine. Promethazine and 
diphenhydramine were shown to inhibit the CYP450 enzyme system, resulting in the decreased 
metabolism of these drugs, causing them to stay in the body longer than usual, increasing the risk 
of an interaction with an opioid. "These interactions may result from the pharmacokinetic 
interactions as well as synergistic effects of opioid use in combination with an antihistamine 
medication" (McCance-Katz et al.,2010). While there is not sufficient literature on these drugs 
and how they may interact with opiates, these medications have similar characteristics as those 
shown to cause interactions with opioids.   
            There have been minimal reports of antipsychotic medications interacting with opioids 
due to the differences in the pathways used for the metabolism of these drugs. Antipsychotics 
such as risperidone, clozapine, aripiprazole, olanzapine, and ziprasidone have not been shown to 
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cause interactions with opioid medications. Some side effects may occur as a result of increased 
sedation or cognitive dysfunction but are only seen when the two medications are given 
simultaneously. (McCance-Katz et al.,2010). While older antipsychotic medications have not 
shown any interactions with opioids, a newer atypical antipsychotic medication, quetiapine has 
the potential to increase plasma methadone concentrations when given with opioids such as 
methadone. Studies have shown that quetiapine is predominantly metabolized by the cytochrome 
P450 enzyme system, the same pathway that is used for metabolizing opioids (DeVane & 
Nemeroff, 2001). Although there have not been any reports of increased plasma methadone 
levels in individuals treated with quetiapine, the mechanism of methadone clearance could be of 
importance.  
           Anticonvulsant medications, a class of drugs commonly used to treat seizure disorders or 
mental illnesses, have been shown to cause significant drug interactions with opioids. Most 
anticonvulsant medications are shown to induce the cytochrome P450 enzyme system. During 
the metabolism of these drugs, the CYP450 system is induced and hydroxylates or conjugates the 
anticonvulsant, breaking it down into different chemical metabolites. The induction of this 
enzyme system leads to a higher clearance of the anticonvulsant medication and other 
medications metabolized by this system, such as methadone. Due to this, larger doses of 
methadone are required in patients treated with anticonvulsant medication. It has been shown 
that carbamazepine, phenytoin, and phenobarbital have been associated with opioid withdrawal 
when administered to methadone-maintained patients (Bromfield et al.,2006). Additionally, 
newer anticonvulsant medications such as oxcarbazepine and lamotrigine have not been shown 
to interact with opioids (McCance-Katz et al.,2010).  
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  Psychostimulants, which are commonly prescribed for attention deficit hyperactivity 
disorder, have not been shown to produce interactions with opioid medications. However, drugs 
of abuse that also fall under the stimulant category, such as cocaine, were shown to deplete 
buprenorphine concentrations. These interactions may be a result of cocaine inducing 
buprenorphine metabolism through CYP450. Another possible way this occurs is due to the 
vasoconstrictive effects of cocaine. Buprenorphine administered through sublingual routes is not 
absorbed appropriately as a result of the vasoconstriction caused by cocaine. (McCance-Katz et 
al.,2010). Methamphetamine, another drug of abuse that falls under the stimulant category, has 
not been shown to interact with opioid medications.  
            While it has been shown that opioid medications are a great source of pain relief, they 
can also cause severe interactions when taken simultaneously with other substances. Most 
patients who are prescribed opioid medications for pain management are prescribed a 
combination of other medications as well. These combinations generally imply a higher risk of 
drug interactions that can cause differences in the therapeutic effects of the drug (Solhaug & 
Molden, 2017). Research has shown that some opioid medications inhibit the gastrointestinal 
system and can consequently decrease the absorption of other substances. Additionally, some 
opioids can act synergistically with other medications that have analgesic or sedative effects, 
resulting in a significant increase in these effects. While we know that drug interactions due to 
pharmacokinetic interactions affect drug transport through the membrane along with the 
Cytochrome P450 (CYP 450) enzyme system, our knowledge regarding the role of this enzyme 
system is still minimal. Although we cannot precisely predict how an individual will respond to 
the effects caused by opioids interacting with other medications, it is crucial to understand what 
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potential interactions exist between opioids and other substances when prescribing these 
medications to patients. (Heiskanen& Kalso, 2012).  
 
                         POTENTIAL COMPLICATIONS FROM OPIOID USAGE 
           When trying to manage pain by using opioid medications, they can act peripherally or 
centrally. Opioids act on the peripheral sources of pain by reducing the stimuli that cause pain 
sensations, or on the central sources by concealing the perception of pain (Solhaug & Molden, 
2017). Individual differences can cause discrepancies in their analgesic properties, and the 
tolerability of opioids can vary due to factors such as age, weight, gender, and organ function. 
Additionally, genetic variabilities can cause differences in their clinical effects and how an 
individual will respond to the medication over time. Genetic variations that change the 
distribution of the opioid throughout the body are known as "genetic causes for changed 
pharmacokinetics of the opioid" administered (Lötsch et al., 2012). Such polymorphisms can 
affect the function of the membrane transporters, modifying the bioavailability of the opioid in 
the body. Furthermore, these polymorphisms can also affect the distribution and elimination of 
the opioid administered. While the adverse effects of this class of polymorphisms are minimal, 
the opioid quantity administered may not be sufficient to produce the desired analgesic effects. 
The effects of this can potentially be avoided by altering the dosage to meet the needs of the 
individual. Once an opioid has been administered, it is broken down into different metabolites 
and travel through the bloodstream to its target receptor sites; at the receptor, the opioid will 
produce its desired effects. Differences in the genetic makeup of an individual can affect the 
pharmacodynamics of the opioid. Pharmacogenetics can affect the movement of the opioid 
throughout the body, as well as the opioids mechanism of action and effects on an individual. 
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           Pain perception can vary greatly in different individuals, and while opioids are generally 
very effective in their analgesic properties, they can cause several side effects. Although there 
can be variability in how these side effects will manifest, we can say that constipation, nausea 
and vomiting, sedation, and respiratory depression remain among the most common. In addition 
to these common side effects, it has been noted that bladder dysfunction, psychomotor changes, 
cardiovascular effects, and hormonal changes have also been seen in patients receiving opioid 
therapy. While we cannot predict which patients will experience specific side effects, if any, 
recent findings have given us better insight into what can be expected.  
           Constipation is one of the most common side effects associated with opioid usage, 
"occurring in 40% to 95% of patients treated with opioids". Although constipation can often be 
dismissed as a minor side effect, the long-term consequences of constipation can result in 
significant adverse effects for the patient. This side effect is due to opioids acting on the mu-
opioid receptor in the gastrointestinal tract and their effects on the CNS, which are thought to 
slow gut motility. Additionally, opioids act on the enteric nervous system to limit gut motility 
peripherally. Unlike some opioid side effects, opioid-induced constipation is not one that is 
likely to improve over time. While there are plenty of stool softeners available that can be 
prescribed to patients experiencing opioid-induced constipation, a "novel approach" to managing 
this side effect includes blocking opioid receptors in the peripheral gastrointestinal tract with 
opioid receptor antagonists (Benyamin et al., 2008). Two new mu-receptor agonists, 
methylnaltrexone and avimopan, are currently under investigation for opioid-induced 
constipation. Methylnaltrexone, a naloxone derivative, works by blocking the peripheral actions 
of opioids while maintaining the analgesic effects they have on the central nervous system. 
  
16 
Avimopan, a selective mu-receptor antagonist, is still under review but has still not shown 
efficacy with opioid-induced constipation.  
While uncommon with most oral opioid analgesic medications, bladder dysfunction can 
be a side effect of opioid usage. Opioid-induced bladder dysfunction is commonly a side effect in 
postoperative patients but can be challenging to assess due to multiple other factors that can 
potentially cause this as well. Urinary retention is more likely to occur when an opioid analgesic 
is given via injection, intravenously, or intramuscularly, which is thought to be due to a decrease 
in detrusor muscle tone and a decreased force of contraction that is caused by opioid 
medications. Additionally, opioids can decrease the sensation of fullness and urge to void, 
inhibiting the void reflex, causing urinary retention. A study done by Rosow and collogues 
showed that opioid-induced bladder changes are partly due to peripheral effects of opioid 
medications and can be reversed by methylnaltrexone. In addition to bladder dysfunction, 
psychomotor performance changes may also be a side effect of opioid therapy. This effect is 
likely due to the sedative effect caused by opioids, making some activities of daily living tasks 
very challenging. When initially starting opioid therapy, it is common that patients experience 
difficulty with psychomotor tasks. While changes in psychomotor abilities can be a severe side 
effect of opioid therapy, it is also one of the side effects that subsides with long- term opioid 
therapy. Furthermore, it has been shown that patients with chronic pain on a fixed opioid 
analgesic therapy were capable of operating automobiles safely during the daytime (Schisler et 
al., 2012). Additionally, in a study done by Fishbain and colleagues, opioid-dependent patients, 
who have some level of opioid tolerance, showed no impairment of psychomotor abilities, even 
immediately following a dose of the opioid (Fishbain et al., 2003). 
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           In addition to the more common side effects of opioids, such as constipation and bladder 
dysfunction, opioid analgesics can also cause cardiovascular effects. While not very common, 
morphine has been associated with some cardiovascular side effects when administered long 
term due to histamine release, resulting in vasodilation and hypotension (Brunton et al., 2006). 
Additionally, parasympathetic stimulation by opioids may contribute to bradycardia that may be 
experienced during opioid therapy and a severe syndrome of QT prolongation known as torsade 
des pointes. This side effect is one that is seen most commonly in patients who are receiving 
methadone assisted treatment, a synthetic opioid used in patients who are battling narcotic drug 
addiction. While we are not able to accurately predict how many patients will experience 
bradycardia or torsade des pointes, due to the severity of these side effects, repeated surface 
EKGs are recommended throughout methadone therapy (Benyamin et al., 2008). Opioid-induced 
hormonal changes can occur with oral, intravenous, transdermal, and intrathecal administration. 
The hormonal effects of opioids can affect both men and women equally and can act on a variety 
of hormones, including but not limited to testosterone, estrogen, luteinizing hormone, 
gonadotrophin-releasing hormone, and cortisol. While there are several hormones affected, there 
is an emphasis on androgen hormones due to their "symptomatic side effects" of opioid therapy. 
Men who are prescribed opioid medications suffer from several side effects, including "sexual 
dysfunction, depression, and decreased energy levels," due to the androgen hormones effected by 
opioid usage (Benyamin et al., 2008). Women are expected to experience similar hormonally 
linked side effects as well as potentially experiencing reduced bone mineral density, which may 
be linked to reduced estrogen levels caused by opioid therapy.   
           Opioid analgesics have proven to be very useful for pain relief, but they also can cause a 
number of side effects. Some complications such as nausea and vomiting, sedation, and 
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constipation do lessen after prolonged exposure to the opioid. Other side effects, such as 
cardiovascular changes and hormonal changes are unlikely to subside throughout the duration of 
opioid therapy, potentially causing long-term physiological changes. Cardiovascular changes can 
also lead to further, more severe complications due to the vasodilatation and QT prolongation. 
Additionally, the symptomatic side effects caused by opioid-induced hormonal changes such as 
reduced bone mineral density are unlikely to be reversible, causing irreversible changes in the 
patient's body.  
                                                               CONCLUSION 
           The opioid epidemic is a severe issue impacting individuals all over the world. While 
opioid analgesics are an efficient source of pain relief, they can exhibit a number of side effects 
depending on the individual. When analyzed, individuals who are prescribed opioids for long 
term therapy show irreversible changes in brain structure, specifically in the regions responsible 
for learning and memory. Prescription opioid-dependent patients also show evidence of 
structural abnormalities in the amygdala, the area responsible for reward processing in the brain. 
When compared to age-matched individuals, opioid-dependent patients showed decreased gray 
matter volume in the bilateral amygdala, along with functional connectivity changes in the 
afferent and efferent pathways of the amygdala. Additionally, prolonged exposure to opioids can 
also lead to decreased sensitivity in the mu-opioid receptor, modified GABAA receptor 
functioning, and altered glutamate receptor targeting. Long term dependence on opioids for their 
analgesic effects can also lead to the development of tolerance or even addiction in some 
patients. While we are not able to foresee which patients will become tolerant to these 
medications, numerous studies have shown that tolerance to different opiates will manifest at 
  
19 
different rates. Once tolerance to an opiate has developed, an increase in the dose of the 
medication may be necessary to produce similar analgesic effects.  
           Another potential area for concern when considering opioid therapy is the increased risk 
for drug-drug interactions. While several interactions can manifest when taking opioid 
medications, these interactions are divided into two groups. Pharmacokinetic interactions, which 
refer to interactions that affect the absorption, metabolism, and excretion of the first drug taken 
and pharmacodynamic, which influence each other's effects directly. Pharmacodynamic 
interactions with opioids are frequent when taking additional central nervous system depressants 
such as antihistamines, benzodiazepines, and barbiturates, causing a resultant increase in the 
therapeutic effects of the opioid administered. It has been shown that a second substance can 
accelerate the metabolism, increasing the plasma concentration of the drug, potentially causing 
toxic effects, an occurrence now referred to as poly- intoxication. Additionally, when adding 
medications that are metabolized by the CYP450 enzyme system may cause variances in the 
metabolism of the opioid taken. For example, the second substance can also inhibit the 
metabolism of the opioid administered, causing the patient to feel insufficient pain relief. This 
can lead to very dangerous, potentially fatal overdoses if the patient self- administers more of the 
opioid. While proper patient education and strict monitoring by the patients' physician can help 
minimize these interactions, it is still something that needs to be taken into consideration when 
putting a patient on opioid therapy for long term pain relief.  
           Opioid analgesics are an up-and-coming class of medications but require strict monitoring 
when administered. Due to the subjective nature of pain, it is difficult to assess which patients 
should be prescribed potent analgesics such as opioid medications, but they should be prescribed 
with extreme caution regardless. We are still very unsure of both the short and long-term 
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implications that opioid therapy entails, and it is essential that we thoroughly examine all other 
options before beginning opioid therapy. The opioid epidemic is a widespread issue that affects 
multiple parts of our healthcare system. Hopefully, as time progresses and more research is done, 
we can get a better understanding of the epidemic as a whole and what we can do to help slow 
the progression.  
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